These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24700981)

  • 1. Compulsory patent licensing and local drug manufacturing capacity in Africa.
    Owoeye OA
    Bull World Health Organ; 2014 Mar; 92(3):214-9. PubMed ID: 24700981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
    McGIVERN L
    Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
    't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
    Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
    Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
    BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options.
    Reichman JH
    J Law Med Ethics; 2009; 37(2):247-63. PubMed ID: 19493070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
    Allard Soto R
    Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The politics behind the implementation of the WTO Paragraph 6 Decision in Canada to increase global drug access.
    Esmail LC; Kohler JC
    Global Health; 2012 Apr; 8():7. PubMed ID: 22472291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Globalization, pharmaceutical pricing, and South African health policy: managing confrontation with U.S. firms and politicians.
    Bond P
    Int J Health Serv; 1999; 29(4):765-92. PubMed ID: 10615573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compulsory Licensing of Pharmaceuticals in High-Income Countries: A Comparative Analysis.
    Qunaj L; Kaltenboeck A; Bach PB
    Milbank Q; 2022 Mar; 100(1):284-313. PubMed ID: 35257415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WTO approves TRIPS amendment on importing under compulsory licensing.
    Herget G
    HIV AIDS Policy Law Rev; 2006 Apr; 11(1):23-4. PubMed ID: 16805011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
    Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
    Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
    Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
    Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the impact of intellectual property rules on access to medicines? A systematic review.
    Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
    Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compulsory licensing and access to drugs.
    Stavropoulou C; Valletti T
    Eur J Health Econ; 2015 Jan; 16(1):83-94. PubMed ID: 24408475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affordability versus innovation: Is compulsory licensing the solution?
    Pandey E; Paul SB
    Int J Risk Saf Med; 2019; 30(4):233-247. PubMed ID: 31658067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Will the Modi government succumb to US and industry pressure to modify its pro-access pharmaceutical patent policy?
    Baker BK
    Expert Opin Ther Pat; 2015 Jun; 25(6):625-8. PubMed ID: 25704359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Learning from practice: compulsory licensing cases and access to medicines.
    Stirner B; Thangaraj H
    Pharm Pat Anal; 2013 Mar; 2(2):195-213. PubMed ID: 24237026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access to medicines and domestic compulsory licensing: learning from Canada and Thailand.
    Kuek V; Phillips K; Kohler JC
    Glob Public Health; 2011; 6(2):111-24. PubMed ID: 20234967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.